<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13844">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363142</url>
  </required_header>
  <id_info>
    <org_study_id>LEX106430</org_study_id>
    <nct_id>NCT00363142</nct_id>
  </id_info>
  <brief_title>A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects</brief_title>
  <official_title>See Detailed Description.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 24-week study to evaluate the efficacy and safety of a once-daily
      ritonavir-boosted fosamprenavir regimen (1400mg/100mg QD) to a 200mg ritonavir-boosted
      fosamprenavir regimen administered either twice-daily or once-daily.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase IIIB, randomized, open-label, parallel group, multi-center, non-inferiority, 24-week
      study to evaluate the safety, efficacy and tolerability of switching from a 200mg
      ritonavir-boosted regimen of LEXIVA (700mg/100mg BID or 1400mg/200mg QD) to a once-daily,
      100mg ritonavir-boosted regimen of LEXIVA (1400mg/100mg QD)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants Not Meeting the Definition of Virologic Failure at or Prior to Week 24</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Virologic failure was defined as two consecutive plasma HIV-1 RNA measures greater than 400 copies/milliliter (mL) separated by at least 2 to 4 week. The percentage of participants not meeting the virologic failure definition was estimated with stratification by the six randomization strata using Mantel-Haenszel weights and the missing/discontinuation equals failure (MD=F) analysis. Missing/discontinuation values were considered failures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Plasma Human Immunodeficiency Virus, Type 1, Ribonucleic Acid (HIV-1 RNA) &lt;400 Copies/mL at Week 24, Time to Loss of Virologic Response (TLOVR) Analysis</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>A blood sample was drawn to determine the amount of plasma HIV-1 RNA virus in copies/mL at week 24. The percentage of participants with plasma HIV-1 RNA &lt;400 copies/mL at Week 24 were determined by the TLOVR algorithm with stratification by the six randomization strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Plasma HIV-1 RNA &lt;50 Copies/mL at Week 24, TLOVR Analysis</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>A blood sample was drawn to determine the amount of plasma HIV-1 RNA virus in copies/mL at week 24. The percentage of participants plasma with HIV-1 RNA &lt;50 copies/mL at Week 24 were determined by the TLOVR algorithm with stratification by the six randomization strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline of log10 Copies/mL Plasma HIV-1 RNA Levels at Week 24, Observed Analysis</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>A blood sample was drawn to determine the amount of plasma HIV-1 RNA virus in copies/mL at week 24. Change from baseline was defined as plasma HIV-1 RNA level at Week 24 minus plasma HIV-1 RNA level at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline of CD4+ Cell Count at Week 24, Observed Analysis</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>A blood sample was drawn to determine the CD4+ cell count at week 24. Change from baseline was defined as CD4+ cell count at Week 24 minus CD4+ cell count at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Treatment Due to Adverse Events Through Week 24</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants who prematurely discontinued study drug due to adverse events was tabulated. Data are summarized by individual adverse event. Adverse events were defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 2-4 Adverse Events Occurring in Greater Than or Equal to 2% of Subjects Through Week 24</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of participants who experienced any grades 2 to 4 adverse events was tabulated. Adverse events were graded based on the Division of Acquired Immunodeficiency Syndrome (AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol, High Density Lipoprotein (HDL), and Triglycerides at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>A blood sample was drawn to determine the cholesterol, HDL, triglycerides levels at Week 24. Percent change in total blood cholesterol, HDL, and triglycerides was defined as (lipid level at Week 24 minus level at baseline) divided by level at baseline x 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Low Density Lipoprotein (LDL) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>A blood sample was drawn to determine the LDL level at Week 24. Percent change in LDL was defined as (LDL level at Week 24 minus level at baseline) divided by level at baseline x 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Plasma HIV-1 RNA Genotypic Mutations and Phenotypic Resistance at Time of Virologic Failure Not Present at Baseline</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>A blood sample was drawn for subjects failing to respond to therapy and the mutations present in the virus were identified. For each subject, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New mutations that developed at the time of virologic failure were tabulated by drug class.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-State Plasma Levels of Amprenavir (APV) and Ritonavir (RTV) Ctau at Weeks 12 and 24</measure>
    <time_frame>Weeks 12 and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples were drawn at weeks 12 and 24 to determine the plasma levels of APV and RTV. Concentration at the end of the dosing interval at steady state (Ctau) was presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>HIV Infection</condition>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>FPV/r200</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fosamprenavir/ritonavir (either 700/100mg BID or 1400/200mg QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FPV/r100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fosamprenavir/ritonavir 1400/100mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Half-boosted Fosamprenavir</intervention_name>
    <description>Once daily, reduced dose ritonavir-boosted fosamprenavir</description>
    <arm_group_label>FPV/r100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Full Boosted Fosamprenavir</intervention_name>
    <description>Full ritonavir-boosted fosamprenavir</description>
    <arm_group_label>FPV/r200</arm_group_label>
    <other_name>Fosamprenavir</other_name>
    <other_name>ritonavir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Subjects with HIV-1 infection.

          -  Are willing and able to understand and provide written consent prior to participation
             in this study.

        Exclusion criteria:

          -  Are pregnant or breastfeeding.

          -  Have an active AIDS condition, pancreatitis, poor kidney function, or clinically
             relevant hepatitis.

          -  Have certain medical conditions that may make participation unsafe.

          -  Take medication that may interact with the study medication.

          -  Have a history of allergy to any of the study drugs or any excipients therein.

          -  Other inclusion/exclusion criteria to be evaluated by the physician.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46280</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229-5299</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ponce</city>
        <zip>00731</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00909-1711</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>October 21, 2010</lastchanged_date>
  <firstreceived_date>August 11, 2006</firstreceived_date>
  <firstreceived_results_date>June 11, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>E.D. Derilus; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <keyword>HIV-1 LEXIVA Ritonavir Once-daily</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fosamprenavir</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were stratified prior to randomization according to baseline regimen (700 milligrams [mg]/100 mg twice a day [BID] or 1400 mg/200 mg once a day [QD]) and previous regimen (no other prior protease inhibitor [PI], non-boosted PI, or boosted PI). Results are reported for the 209 participants (out of 211 enrolled) receiving study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FPV/r100</title>
          <description>Fosamprenavir (FPV)/ritonavir (RTV) 1400mg/100mg once a day (QD)</description>
        </group>
        <group group_id="P2">
          <title>FPV/r200</title>
          <description>FPV/RTV (either 700mg/100mg twice a day [BID] or 1400mg/200mg QD)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FPV/r100</title>
          <description>Fosamprenavir (FPV)/ritonavir (RTV) 1400mg/100mg once a day (QD)</description>
        </group>
        <group group_id="B2">
          <title>FPV/r200</title>
          <description>FPV/RTV (either 700mg/100mg twice a day [BID] or 1400mg/200mg QD)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="140"/>
                <measurement group_id="B2" value="69"/>
                <measurement group_id="B3" value="209"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="44.9" spread="10.52"/>
                <measurement group_id="B2" value="44.3" spread="8.9"/>
                <measurement group_id="B3" value="44.7" spread="10.00"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="42"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="107"/>
                <measurement group_id="B2" value="60"/>
                <measurement group_id="B3" value="167"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>African American/African heritage</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="62"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>American Indian/Alaskan native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian - South East Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White - Arabic/North African</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White - White/Caucasian/European</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="95"/>
                <measurement group_id="B2" value="44"/>
                <measurement group_id="B3" value="139"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Mixed race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="42"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="109"/>
                <measurement group_id="B2" value="58"/>
                <measurement group_id="B3" value="167"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Not Meeting the Definition of Virologic Failure at or Prior to Week 24</title>
        <description>Virologic failure was defined as two consecutive plasma HIV-1 RNA measures greater than 400 copies/milliliter (mL) separated by at least 2 to 4 week. The percentage of participants not meeting the virologic failure definition was estimated with stratification by the six randomization strata using Mantel-Haenszel weights and the missing/discontinuation equals failure (MD=F) analysis. Missing/discontinuation values were considered failures.</description>
        <time_frame>Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat Exposed (ITT-E) Population. Subjects who received at least one dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/r100</title>
            <description>Fosamprenavir (FPV)/ritonavir (RTV) 1400mg/100mg once a day (QD)</description>
          </group>
          <group group_id="O2">
            <title>FPV/r200</title>
            <description>FPV/RTV (either 700mg/100mg twice a day [BID] or 1400mg/200mg QD)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="140"/>
                  <measurement group_id="O2" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Not Meeting the Definition of Virologic Failure at or Prior to Week 24</title>
            <description>Virologic failure was defined as two consecutive plasma HIV-1 RNA measures greater than 400 copies/milliliter (mL) separated by at least 2 to 4 week. The percentage of participants not meeting the virologic failure definition was estimated with stratification by the six randomization strata using Mantel-Haenszel weights and the missing/discontinuation equals failure (MD=F) analysis. Missing/discontinuation values were considered failures.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="92.1"/>
                  <measurement group_id="O2" value="94.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority of FPV/r100 to FPV/r200 would be declared if the lower limit of the 2-sided 95% confidence interval on the difference in percentage of participants not meeting the virologic failure definition [FPV/r100 minus FPV/r200] was -12% or greater.</non_inferiority_desc>
            <param_type>Difference in the percentages</param_type>
            <param_value>-2.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.36</ci_lower_limit>
            <ci_upper_limit>5.12</ci_upper_limit>
            <estimate_desc>Difference in percentages = percentage in Arm 1 minus percentage in Arm 2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Plasma Human Immunodeficiency Virus, Type 1, Ribonucleic Acid (HIV-1 RNA) &lt;400 Copies/mL at Week 24, Time to Loss of Virologic Response (TLOVR) Analysis</title>
        <description>A blood sample was drawn to determine the amount of plasma HIV-1 RNA virus in copies/mL at week 24. The percentage of participants with plasma HIV-1 RNA &lt;400 copies/mL at Week 24 were determined by the TLOVR algorithm with stratification by the six randomization strata.</description>
        <time_frame>Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/r100</title>
            <description>Fosamprenavir (FPV)/ritonavir (RTV) 1400mg/100mg once a day (QD)</description>
          </group>
          <group group_id="O2">
            <title>FPV/r200</title>
            <description>FPV/RTV (either 700mg/100mg twice a day [BID] or 1400mg/200mg QD)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="140"/>
                  <measurement group_id="O2" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Plasma Human Immunodeficiency Virus, Type 1, Ribonucleic Acid (HIV-1 RNA) &lt;400 Copies/mL at Week 24, Time to Loss of Virologic Response (TLOVR) Analysis</title>
            <description>A blood sample was drawn to determine the amount of plasma HIV-1 RNA virus in copies/mL at week 24. The percentage of participants with plasma HIV-1 RNA &lt;400 copies/mL at Week 24 were determined by the TLOVR algorithm with stratification by the six randomization strata.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Plasma HIV-1 RNA &lt;400 copies/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92"/>
                  <measurement group_id="O2" value="94.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HIV-1 RNA greater than or equal to 400 copies/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="5.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Plasma HIV-1 RNA &lt;50 Copies/mL at Week 24, TLOVR Analysis</title>
        <description>A blood sample was drawn to determine the amount of plasma HIV-1 RNA virus in copies/mL at week 24. The percentage of participants plasma with HIV-1 RNA &lt;50 copies/mL at Week 24 were determined by the TLOVR algorithm with stratification by the six randomization strata.</description>
        <time_frame>Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/r100</title>
            <description>Fosamprenavir (FPV)/ritonavir (RTV) 1400mg/100mg once a day (QD)</description>
          </group>
          <group group_id="O2">
            <title>FPV/r200</title>
            <description>FPV/RTV (either 700mg/100mg twice a day [BID] or 1400mg/200mg QD)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="140"/>
                  <measurement group_id="O2" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Plasma HIV-1 RNA &lt;50 Copies/mL at Week 24, TLOVR Analysis</title>
            <description>A blood sample was drawn to determine the amount of plasma HIV-1 RNA virus in copies/mL at week 24. The percentage of participants plasma with HIV-1 RNA &lt;50 copies/mL at Week 24 were determined by the TLOVR algorithm with stratification by the six randomization strata.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Plasma HIV-1 RNA &lt;50 copies/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="82.9"/>
                  <measurement group_id="O2" value="84.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HIV-1 RNA greater than or equal to 50 copies/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17.1"/>
                  <measurement group_id="O2" value="15.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline of log10 Copies/mL Plasma HIV-1 RNA Levels at Week 24, Observed Analysis</title>
        <description>A blood sample was drawn to determine the amount of plasma HIV-1 RNA virus in copies/mL at week 24. Change from baseline was defined as plasma HIV-1 RNA level at Week 24 minus plasma HIV-1 RNA level at baseline.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT-E Population - Observed Analysis, available data from those subjects who had values at baseline and at Week 24</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/r100</title>
            <description>Fosamprenavir (FPV)/ritonavir (RTV) 1400mg/100mg once a day (QD)</description>
          </group>
          <group group_id="O2">
            <title>FPV/r200</title>
            <description>FPV/RTV (either 700mg/100mg twice a day [BID] or 1400mg/200mg QD)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="131"/>
                  <measurement group_id="O2" value="66"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline of log10 Copies/mL Plasma HIV-1 RNA Levels at Week 24, Observed Analysis</title>
            <description>A blood sample was drawn to determine the amount of plasma HIV-1 RNA virus in copies/mL at week 24. Change from baseline was defined as plasma HIV-1 RNA level at Week 24 minus plasma HIV-1 RNA level at baseline.</description>
            <units>log10 copies/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.015" spread="0.388"/>
                  <measurement group_id="O2" value="-0.022" spread="0.130"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline of CD4+ Cell Count at Week 24, Observed Analysis</title>
        <description>A blood sample was drawn to determine the CD4+ cell count at week 24. Change from baseline was defined as CD4+ cell count at Week 24 minus CD4+ cell count at baseline.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT-E Population - Observed Analysis, available data from those subjects who had values at baseline and at Week 24</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/r100</title>
            <description>Fosamprenavir (FPV)/ritonavir (RTV) 1400mg/100mg once a day (QD)</description>
          </group>
          <group group_id="O2">
            <title>FPV/r200</title>
            <description>FPV/RTV (either 700mg/100mg twice a day [BID] or 1400mg/200mg QD)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="132"/>
                  <measurement group_id="O2" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Median Change From Baseline of CD4+ Cell Count at Week 24, Observed Analysis</title>
            <description>A blood sample was drawn to determine the CD4+ cell count at week 24. Change from baseline was defined as CD4+ cell count at Week 24 minus CD4+ cell count at baseline.</description>
            <units>cells/mm3</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11.5" spread="0.073" lower_limit="-386" upper_limit="407"/>
                  <measurement group_id="O2" value="15" spread="0.194" lower_limit="-201" upper_limit="454"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued Treatment Due to Adverse Events Through Week 24</title>
        <description>The number of participants who prematurely discontinued study drug due to adverse events was tabulated. Data are summarized by individual adverse event. Adverse events were defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>Baseline through Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population: all randomized subjects who consumed at least one dose of study drug and was analyzed according to the treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/r100</title>
            <description>Fosamprenavir (FPV)/ritonavir (RTV) 1400mg/100mg once a day (QD)</description>
          </group>
          <group group_id="O2">
            <title>FPV/r200</title>
            <description>FPV/RTV (either 700mg/100mg twice a day [BID] or 1400mg/200mg QD)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="142"/>
                  <measurement group_id="O2" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Discontinued Treatment Due to Adverse Events Through Week 24</title>
            <description>The number of participants who prematurely discontinued study drug due to adverse events was tabulated. Data are summarized by individual adverse event. Adverse events were defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Metastatic neoplasms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Central nervous system lesion</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 2-4 Adverse Events Occurring in Greater Than or Equal to 2% of Subjects Through Week 24</title>
        <description>The number of participants who experienced any grades 2 to 4 adverse events was tabulated. Adverse events were graded based on the Division of Acquired Immunodeficiency Syndrome (AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events.</description>
        <time_frame>Baseline through Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/r100</title>
            <description>Fosamprenavir (FPV)/ritonavir (RTV) 1400mg/100mg once a day (QD)</description>
          </group>
          <group group_id="O2">
            <title>FPV/r200</title>
            <description>FPV/RTV (either 700mg/100mg twice a day [BID] or 1400mg/200mg QD)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="142"/>
                  <measurement group_id="O2" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Grade 2-4 Adverse Events Occurring in Greater Than or Equal to 2% of Subjects Through Week 24</title>
            <description>The number of participants who experienced any grades 2 to 4 adverse events was tabulated. Adverse events were graded based on the Division of Acquired Immunodeficiency Syndrome (AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any event</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bronchitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sinusitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Upper respiratory tract infection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blood glucose increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Depression</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Influenza</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Low density lipoprotein increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nasopharyngitis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Otitis media</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Back pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypercholesterolemia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Insomnia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol, High Density Lipoprotein (HDL), and Triglycerides at Week 24</title>
        <description>A blood sample was drawn to determine the cholesterol, HDL, triglycerides levels at Week 24. Percent change in total blood cholesterol, HDL, and triglycerides was defined as (lipid level at Week 24 minus level at baseline) divided by level at baseline x 100%.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/r100</title>
            <description>Fosamprenavir (FPV)/ritonavir (RTV) 1400mg/100mg once a day (QD)</description>
          </group>
          <group group_id="O2">
            <title>FPV/r200</title>
            <description>FPV/RTV (either 700mg/100mg twice a day [BID] or 1400mg/200mg QD)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="123"/>
                  <measurement group_id="O2" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Total Cholesterol, High Density Lipoprotein (HDL), and Triglycerides at Week 24</title>
            <description>A blood sample was drawn to determine the cholesterol, HDL, triglycerides levels at Week 24. Percent change in total blood cholesterol, HDL, and triglycerides was defined as (lipid level at Week 24 minus level at baseline) divided by level at baseline x 100%.</description>
            <units>Percent change</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Total cholesterol</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.5" lower_limit="-41.8" upper_limit="31.3"/>
                  <measurement group_id="O2" value="0.7" lower_limit="-35.4" upper_limit="91"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HDL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.1" lower_limit="-34.8" upper_limit="47.4"/>
                  <measurement group_id="O2" value="0" lower_limit="-34.1" upper_limit="31.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-13.5" lower_limit="-87.7" upper_limit="169.2"/>
                  <measurement group_id="O2" value="-0.6" lower_limit="-52.2" upper_limit="191.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Low Density Lipoprotein (LDL) at Week 24</title>
        <description>A blood sample was drawn to determine the LDL level at Week 24. Percent change in LDL was defined as (LDL level at Week 24 minus level at baseline) divided by level at baseline x 100%.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/r100</title>
            <description>Fosamprenavir (FPV)/ritonavir (RTV) 1400mg/100mg once a day (QD)</description>
          </group>
          <group group_id="O2">
            <title>FPV/r200</title>
            <description>FPV/RTV (either 700mg/100mg twice a day [BID] or 1400mg/200mg QD)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="115"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Low Density Lipoprotein (LDL) at Week 24</title>
            <description>A blood sample was drawn to determine the LDL level at Week 24. Percent change in LDL was defined as (LDL level at Week 24 minus level at baseline) divided by level at baseline x 100%.</description>
            <units>Percent change</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="-47" upper_limit="103.8"/>
                  <measurement group_id="O2" value="2.1" lower_limit="-60.5" upper_limit="142.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Plasma HIV-1 RNA Genotypic Mutations and Phenotypic Resistance at Time of Virologic Failure Not Present at Baseline</title>
        <description>A blood sample was drawn for subjects failing to respond to therapy and the mutations present in the virus were identified. For each subject, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New mutations that developed at the time of virologic failure were tabulated by drug class.</description>
        <time_frame>Baseline through Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants in the ITT-E Population who met the virologic failure definition</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/r100</title>
            <description>Fosamprenavir (FPV)/ritonavir (RTV) 1400mg/100mg once a day (QD)</description>
          </group>
          <group group_id="O2">
            <title>FPV/r200</title>
            <description>FPV/RTV (either 700mg/100mg twice a day [BID] or 1400mg/200mg QD)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Plasma HIV-1 RNA Genotypic Mutations and Phenotypic Resistance at Time of Virologic Failure Not Present at Baseline</title>
            <description>A blood sample was drawn for subjects failing to respond to therapy and the mutations present in the virus were identified. For each subject, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New mutations that developed at the time of virologic failure were tabulated by drug class.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady-State Plasma Levels of Amprenavir (APV) and Ritonavir (RTV) Ctau at Weeks 12 and 24</title>
        <description>Blood samples were drawn at weeks 12 and 24 to determine the plasma levels of APV and RTV. Concentration at the end of the dosing interval at steady state (Ctau) was presented.</description>
        <time_frame>Weeks 12 and 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>PK Parameter (Ctau) Population - Participants in the ITT-E Population who underwent PK sampling and had evaluable APV or RTV Ctau data.</population>
        <group_list>
          <group group_id="O1">
            <title>FPV/r100</title>
            <description>Fosamprenavir (FPV)/ritonavir (RTV) 1400/100mg once a day (QD)</description>
          </group>
          <group group_id="O2">
            <title>FPV/r200</title>
            <description>FPV/RTV (either 700/100mg twice a day [BID] or 1400/200mg QD)</description>
          </group>
          <group group_id="O3">
            <title>FPV/RTV 700/100 mg BID</title>
            <description>Twice daily FPV regimen boosted with a reduced dose of RTV 100 mg</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Steady-State Plasma Levels of Amprenavir (APV) and Ritonavir (RTV) Ctau at Weeks 12 and 24</title>
            <description>Blood samples were drawn at weeks 12 and 24 to determine the plasma levels of APV and RTV. Concentration at the end of the dosing interval at steady state (Ctau) was presented.</description>
            <units>micrograms/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Week 12 APV Ctau</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.38" lower_limit="1.09" upper_limit="1.74"/>
                  <measurement group_id="O2" value="1.28" lower_limit="0.69" upper_limit="2.37"/>
                  <measurement group_id="O3" value="1.35" lower_limit="0.44" upper_limit="4.11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24 APV Ctau</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.27" lower_limit="0.99" upper_limit="1.62"/>
                  <measurement group_id="O2" value="1.49" lower_limit="1.02" upper_limit="2.18"/>
                  <measurement group_id="O3" value="2.38" lower_limit="1.68" upper_limit="3.37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12 RTV Ctau</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.026" lower_limit="0" upper_limit="0.286"/>
                  <measurement group_id="O2" value="0.050" lower_limit="0" upper_limit="0.346"/>
                  <measurement group_id="O3" value="0.228" lower_limit="0" upper_limit="0.568"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24 RTV Ctau</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.022" lower_limit="0" upper_limit="2.49"/>
                  <measurement group_id="O2" value="0.056" lower_limit="0" upper_limit="0.634"/>
                  <measurement group_id="O3" value="0.203" lower_limit="0" upper_limit="1.10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>FPV/r100</title>
          <description>Fosamprenavir (FPV)/ritonavir (RTV) 1400mg/100mg once a day (QD)</description>
        </group>
        <group group_id="E2">
          <title>FPV/r200</title>
          <description>FPV/RTV (either 700mg/100mg twice a day [BID] or 1400mg/200mg QD)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7"/>
                <counts group_id="E2" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MeDRA">Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18"/>
                <counts group_id="E2" subjects_affected="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
